Media stories about Apricus Biosciences (NASDAQ:APRI) have been trending somewhat positive on Saturday, Accern reports. The research firm ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Apricus Biosciences earned a media sentiment score of 0.09 on Accern’s scale. Accern also gave news coverage about the company an impact score of 46.6930389651483 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Several equities analysts recently issued reports on the company. HC Wainwright restated a “buy” rating and set a $4.50 price target on shares of Apricus Biosciences in a research report on Friday, November 3rd. Zacks Investment Research upgraded Apricus Biosciences from a “hold” rating to a “buy” rating and set a $1.75 price target on the stock in a research report on Tuesday, October 31st.

Apricus Biosciences (NASDAQ:APRI) traded up $0.01 on Friday, reaching $1.61. The company had a trading volume of 37,862 shares, compared to its average volume of 126,959. Apricus Biosciences has a fifty-two week low of $0.86 and a fifty-two week high of $4.07.

Apricus Biosciences (NASDAQ:APRI) last posted its quarterly earnings results on Thursday, November 2nd. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.15). During the same period last year, the company posted ($0.19) earnings per share. analysts predict that Apricus Biosciences will post -0.6 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This article was first published by Watch List News and is owned by of Watch List News. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The correct version of this article can be read at https://www.watchlistnews.com/apricus-biosciences-apri-receiving-somewhat-positive-press-coverage-analysis-shows/1726294.html.

Apricus Biosciences Company Profile

Apricus Biosciences, Inc is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT.

Insider Buying and Selling by Quarter for Apricus Biosciences (NASDAQ:APRI)

Receive News & Ratings for Apricus Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apricus Biosciences Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.